The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction

Acute ST-segment elevation myocardial infarction (STEMI) is the most lethal coronary heart disease with vascular endothelium dysfunction and inflammation in the disease development process. Endothelial cell-specific molecule 1 (ESM-1) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are important for the diagnosis and characterization of STEMI. To date, no studies have reported the correlation between ESM-1 and Lp-PLA2 levels in patients with STEMI, which may be an important predictor of the fatal disease. To measure the level of serum ESM-1 and Lp-PLA2, and to evaluate the relationship and the clinical significance of these two biomarkers in patients with acute STEMI, 37 inpatients with acute STEMI were sequentially enrolled in the research group and 24 study objects with normal coronary artery function were included in the control group. The measurement of the relative parameters was done by enzyme-linked immunosorbent assay using blood samples taken from the median cubital vein while the inpatients were enrolled. The levels of serum SEM-1 and Lp-PLA2 were significantly higher in patients with acute STEMI than in study objects with normal coronary artery function (P < 0.05). A significant correlation of serum SEM-1 and Lp-PLA2 was observed, leading to close linearity (r(2) = 0.8131,P < 0.0001). In conclusion, the endothelium dysfunction factor ESM-1 and inflammatory factor Lp-PLA2 are significantly higher and correlated in patients with acute STEMI. These two factors could be novel and effective biomarkers for acute STEMI diagnosis and evaluation.

Automated summary

This study found that the levels of ESM-1 and Lp-PLA2 are significantly elevated in patients with acute STEMI, and there is a significant correlation between the two biomarkers. This suggests that ESM-1 and Lp-PLA2 could be novel and effective biomarkers for the diagnosis and evaluation of acute STEMI.